Advanced Depression Treatment Access Expands
Quick Facts
Why Are Advanced Depression Treatments Expanding?
Depression remains one of the most common causes of disability worldwide, with the World Health Organization estimating that roughly 280 million people live with the condition. In the United States, National Institute of Mental Health data indicate that tens of millions of adults experience major depressive episodes, creating sustained demand for timely diagnosis, therapy, medication management and higher-intensity care when symptoms persist.
Recent clinic expansion, including new outpatient centers offering advanced treatment services, reflects a practical access issue: many patients need more than brief medication visits but do not require inpatient hospitalization. The clinical challenge is to expand availability without reducing standards for evaluation, suicide-risk assessment, comorbidity screening, medication review and continuity of care.
What Are TMS and Esketamine Used For?
Transcranial magnetic stimulation, or TMS, uses focused magnetic pulses to stimulate brain circuits involved in mood regulation. It is typically delivered in repeated outpatient sessions and is considered noninvasive because it does not require surgery, anesthesia or implanted hardware. Clinical use is most established for major depressive disorder when symptoms have not improved sufficiently after antidepressant treatment.
Esketamine is a prescription nasal spray approved by the FDA for treatment-resistant depression in specific clinical circumstances. Because it can cause sedation, dissociation and blood pressure changes, it is administered under medical supervision through a restricted safety program rather than as a take-home medication. These safeguards matter because advanced treatments can be useful, but they are not substitutes for careful psychiatric assessment.
How Should Patients Evaluate New Mental Health Clinics?
Access is only one part of quality mental health care. Patients considering advanced treatment should ask whether the clinic performs a full diagnostic evaluation, reviews prior medication trials, screens for bipolar disorder and substance use, and has a clear plan for emergencies or worsening suicidal thoughts. These steps help prevent inappropriate treatment and improve the chance that care is matched to the person’s condition.
For anxiety disorders, OCD and PTSD, evidence-based psychotherapy remains central, including cognitive behavioral therapy and exposure-based approaches when appropriate. Medication, neuromodulation and newer interventions may have roles for selected patients, but the strongest care models combine accurate diagnosis, measurable symptom tracking, shared decision-making and follow-up long enough to detect both benefit and harm.
Frequently Asked Questions
No. TMS uses magnetic stimulation and does not require anesthesia or intentionally trigger a seizure. Electroconvulsive therapy is a different medical treatment that can be highly effective for severe depression but is performed under anesthesia with closer medical monitoring.
Esketamine may be considered for adults with treatment-resistant depression who meet FDA-approved criteria and can receive supervised dosing. A clinician should review diagnosis, blood pressure, medication history, substance use risk and safety concerns before treatment.
Usually no. Many patients still need psychotherapy, medication management, sleep and substance-use assessment, and follow-up care. Advanced treatments are best viewed as part of a broader care plan for selected patients.
References
- PR Newswire. Serenity Mental Health Centers Opens Alexandria Clinic, Expanding Access to Advanced Treatment for Depression, Anxiety, OCD and PTSD. June 2026.
- World Health Organization. Depression fact sheet.
- National Institute of Mental Health. Major Depression.
- U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. 2019.